The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Renal function is preserved better compared with radical nephrectomy even when tumors are larger than the traditional 4 cm cutoff.
Renal tumors occur at a frequency 7.5 times greater in lithium-treated patients than in the general population, French study shows.
At last follow-up, 41 of 43 patients who underwent partial nephrectomy did not require dialysis.
Patients with levels of 161.5 mg/dL or greater had a 43% decreased risk of death from renal cell carcinoma than those with lower levels.
The finding emerged from a French study of 213 patients with metastatic renal cell carcinoma.
Added to sunitinib, it prolongs progression-free and overall survival in patients with unfavorable-risk metastatic renal cell carcinoma.
Drug found to benefit children with renal angiomyolipomas associated with tuberous sclerosis complex.
The risk of cancer-specific death at 1 year was 48% and 23% for patients whose disease recurred at 3 months and 3 years, respectively.
The proportion of patients undergoing the procedure has stayed at 6%-7% annually.
Larger tumor size, male sex, and higher nephrometry score indicate a greater likelihood that a renal mass is malignant, researchers report.
The DISSRM score may be an easy-to-calculate surrogate for competing risk mortality.
Open procedures, preoperative dialysis, and higher ASA score were significant predictors of readmission after radical nephrectomy.
Following guidelines from the AUA and NCCN would miss many cases of disease recurrence following surgery, study suggests.
Patients of lower socioeconomic status present with larger tumors, higher T stage, positive lymph nodes.
Statin use decreases the risk of disease progression after surgery for localized RCC.